. mTOR Pathway Somatic Pathogenic Variants in Focal Malformations of Cortical Development: Novel Variants, Topographic Mapping, and Clinical Outcomes. Neurol Genet. 2023;9:e200103 pubmed publisher

Li T, Wang Q, Gao A, Li X, Sun Y, Mottis A, et al. Lysosomes mediate the mitochondrial UPR via mTORC1-dependent ATF4 phosphorylation. Cell Discov. 2023;9:92 pubmed publisher

Nicastro R, Broh xe9 e L, Alba J, N xfc chel J, Figlia G, Kipschull S, et al. Malonyl-CoA is a conserved endogenous ATP-competitive mTORC1 inhibitor. Nat Cell Biol. 2023;25:1303-1318 pubmed publisher

Liu H, Du H, Khabibullin D, Zarei M, Wei K, Freeman G, et al. mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion. Nat Commun. 2023;14:1214 pubmed publisher

Fujita A, Kato M, Sugano H, Iimura Y, Suzuki H, Tohyama J, et al. An integrated genetic analysis of epileptogenic brain malformed lesions. Acta Neuropathol Commun. 2023;11:33 pubmed publisher

Zhang S, Lee S, Nie L, Huang Y, Zou G, Jung Y, et al. Lysosomal TMEM9-LAMTOR4-controlled mTOR signaling integrity is required for mammary tumorigenesis. Cancer Commun (Lond). 2022;: pubmed publisher

Yu Z, Chen J, Takagi E, Wang F, Saha B, Liu X, et al. Interactions between mTORC2 core subunits Rictor and mSin1 dictate selective and context-dependent phosphorylation of substrate kinases SGK1 and Akt. J Biol Chem. 2022;298:102288 pubmed publisher

Ganner A, Gehrke C, Klein M, Thegtmeier L, Matulenski T, Wingendorf L, et al. VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma. Sci Rep. 2021;11:14827 pubmed publisher

Nüchel J, Tauber M, Nolte J, Morgelin M, Türk C, Eckes B, et al. An mTORC1-GRASP55 signaling axis controls unconventional secretion to reshape the extracellular proteome upon stress. Mol Cell. 2021;: pubmed publisher

Besterman A, Althoff T, Elfferich P, Gutierrez Mejia I, Sadik J, Bernstein J, et al. Functional and structural analyses of novel Smith-Kingsmore Syndrome-Associated MTOR variants reveal potential new mechanisms and predictors of pathogenicity. PLoS Genet. 2021;17:e1009651 pubmed publisher

Zhang H, Yi J, Huang H, Park S, Park S, Kwon W, et al. Rhein Suppresses Colorectal Cancer Cell Growth by Inhibiting the mTOR Pathway In Vitro and In Vivo. Cancers (Basel). 2021;13: pubmed publisher

Yeh C, Bellon M, Wang F, Zhang H, Fu L, Nicot C. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells. Mol Cancer. 2020;19:139 pubmed publisher

Kim D, Park G, Huuhtanen J, Lundgren S, Khajuria R, Hurtado A, et al. Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease. Nat Commun. 2020;11:2246 pubmed publisher

Xiao B, Zuo D, Hirukawa A, Cardiff R, Lamb R, Sonenberg N, et al. Rheb1-Independent Activation of mTORC1 in Mammary Tumors Occurs through Activating Mutations in mTOR. Cell Rep. 2020;31:107571 pubmed publisher

Lin J, Jiao A, Lv W, Zhang C, Shi Y, Yang Z, et al. Pentapeptide Protects INS-1 Cells From hIAPP-Mediated Apoptosis by Enhancing Autophagy Through mTOR Pathway. Front Pharmacol. 2019;10:896 pubmed publisher

Xu M, Almasi S, Yang Y, Yan C, Sterea A, Rizvi Syeda A, et al. The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways. Cell Calcium. 2019;79:80-88 pubmed publisher

Kovalski J, Bhaduri A, Zehnder A, Neela P, Che Y, Wozniak G, et al. The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2. Mol Cell. 2019;73:830-844.e12 pubmed publisher

Li X, Zhu G, Yao X, Wang N, Hu R, Kong Q, et al. Celastrol induces ubiquitin-dependent degradation of mTOR in breast cancer cells. Onco Targets Ther. 2018;11:8977-8985 pubmed publisher

Jung S, Hwang H, Kang D, Park H, Lee H, Jeong D, et al. mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53. Oncogene. 2019;38:1639-1650 pubmed publisher

Bruning U, Morales Rodriguez F, Kalucka J, Goveia J, Taverna F, Queiroz K, et al. Impairment of Angiogenesis by Fatty Acid Synthase Inhibition Involves mTOR Malonylation. Cell Metab. 2018;28:866-880.e15 pubmed publisher

Gu Y, Albuquerque C, Braas D, Zhang W, Villa G, Bi J, et al. mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT. Mol Cell. 2017;67:128-138.e7 pubmed publisher

Brown M, Gromeier M. MNK Controls mTORC1:Substrate Association through Regulation of TELO2 Binding with mTORC1. Cell Rep. 2017;18:1444-1457 pubmed publisher

Mimoto R, Nihira N, Hirooka S, Takeyama H, Yoshida K. Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR. Cancer Lett. 2017;384:27-38 pubmed publisher

Chen Y, Xu J, Skanderup A, Dong Y, Brannon A, Wang L, et al. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nat Commun. 2016;7:13131 pubmed publisher

Su K, Cao J, Tang Z, Dai S, He Y, Sampson S, et al. HSF1 critically attunes proteotoxic stress sensing by mTORC1 to combat stress and promote growth. Nat Cell Biol. 2016;18:527-39 pubmed publisher

Bhardwaj A, Ganesan N, Tachibana K, Rajapakshe K, Albarracin C, Gunaratne P, et al. Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling. PLoS ONE. 2015;10:e0127678 pubmed publisher

Li C, Chen J, Lu B, Shi Z, Wang H, Zhang B, et al. Molecular switch role of Akt in Polygonatum odoratum lectin-induced apoptosis and autophagy in human non-small cell lung cancer A549 cells. PLoS ONE. 2014;9:e101526 pubmed publisher

Jha A, Ahuja M, Patel S, Brailoiu E, Muallem S. Convergent regulation of the lysosomal two-pore channel-2 by Mg²?, NAADP, PI(3,5)P? and multiple protein kinases. EMBO J. 2014;33:501-11 pubmed publisher

Wu X, Bhayani M, Dodge C, Nicoloso M, Chen Y, Yan X, et al. Coordinated targeting of the EGFR signaling axis by microRNA-27a*. Oncotarget. 2013;4:1388-98 pubmed

Vilella Bach M, Nuzzi P, Fang Y, Chen J. The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression. J Biol Chem. 1999;274:4266-72 pubmed